These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28591105)

  • 1. Everything old is new again: the case for imatinib as frontline therapy in 2017.
    Lee SG; Lipton JH
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):302-305. PubMed ID: 28591105
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biology of CML supports second-generation TKIs as frontline treatment.
    Fava C; Saglio G
    Clin Adv Hematol Oncol; 2017 Apr; 15(4):302-307. PubMed ID: 28591106
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.
    Khorashad JS; Tantravahi SK; Yan D; Mason CC; Qiao Y; Eiring AM; Gligorich K; Hein T; Pomicter AD; Reid AG; Kelley TW; Marth GT; O'Hare T; Deininger MW
    Leukemia; 2016 Nov; 30(11):2275-2279. PubMed ID: 27480386
    [No Abstract]   [Full Text] [Related]  

  • 5. What Happens When Imatinib Goes Generic?
    McDougall J; Ramsey SD; Radich J
    J Natl Compr Canc Netw; 2016 Feb; 14(2):128-31. PubMed ID: 26850483
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 7. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
    Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
    Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
    [No Abstract]   [Full Text] [Related]  

  • 8. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
    Raanani P
    Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
    [No Abstract]   [Full Text] [Related]  

  • 9. Racial Differences in Survival of Elderly Adults with Chronic Myeloid Leukemia Before and After the Introduction of Imatinib in the United States.
    Shah BK; Uprety D
    J Am Geriatr Soc; 2016 Apr; 64(4):887-9. PubMed ID: 27100589
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
    Carulli G; Baratè C; Marini A; Ottaviano V; Cervetti G; Fontanelli G; Guerrini F; Arici R; Guerri V; Di Paolo A; Polillo M; Ferreri MI; Galimberti S; Petrini M
    Hematol Oncol; 2015 Dec; 33(4):250-2. PubMed ID: 25256816
    [No Abstract]   [Full Text] [Related]  

  • 11. Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
    Giona F; Malaspina F; Putti MC; Ladogana S; Mura R; Burnelli R; Vacca N; Rizzo L; Bianchi S; Moleti ML; Testi AM; Biondi A; Locatelli F; Saglio G; Foà R
    Br J Haematol; 2020 Mar; 188(6):e101-e105. PubMed ID: 32087030
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
    Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
    Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.
    Klil-Drori AJ; Yin H; Azoulay L; Harnois M; Gratton MO; Busque L; Assouline SE;
    Haematologica; 2019 Jul; 104(7):e293-e295. PubMed ID: 30630987
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
    Singh S; Sharma PK
    Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.
    Breccia M; Colafigli G; Molica M; De Angelis F; Quattrocchi L; Latagliata R; Mancini M; Diverio D; Alimena G
    Br J Haematol; 2016 Jun; 173(6):945-6. PubMed ID: 26304741
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib-Associated Pneumocystis jirovecii Pneumonia in a Patient With Chronic Myeloid Leukemia.
    Daw J; Thapa B; Chahine J; Lak H; Perez O; Nair R; Alomari M; Haddad A
    Am J Ther; 2020; 27(4):e406-e409. PubMed ID: 31356343
    [No Abstract]   [Full Text] [Related]  

  • 17. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 18. Aggregates of Pseudogaucher Cells in a Pediatric Patient With Chronic Myeloid Leukemia.
    Roldán Galiacho V; Moreno Gamiz M; Echebarrria-Barona A
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):224-225. PubMed ID: 34054044
    [No Abstract]   [Full Text] [Related]  

  • 19. Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
    Kaygusuz-Atagunduz I; Toptas T; Yumuk F; Firatli-Tuglular T; Bayik M
    J Cancer Res Ther; 2014; 10(4):1107-8. PubMed ID: 25579564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.